A detailed history of China Universal Asset Management Co., Ltd. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 15,773 shares of AVXL stock, worth $66,088. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,773
Previous 15,773 -0.0%
Holding current value
$66,088
Previous $80,000 -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$4.55 - $6.75 $28,551 - $42,356
6,275 Added 66.07%
15,773 $80,000
Q4 2023

May 21, 2024

SELL
$5.04 - $9.95 $31,626 - $62,436
-6,275 Reduced 39.78%
9,498 $88,000
Q4 2023

Jan 23, 2024

BUY
$5.04 - $9.95 $37,270 - $73,580
7,395 Added 351.64%
9,498 $88,000
Q3 2023

May 21, 2024

BUY
$6.55 - $9.37 $6,838 - $9,782
1,044 Added 98.58%
2,103 $13,000
Q3 2023

Oct 30, 2023

BUY
$6.55 - $9.37 $6,838 - $9,782
1,044 Added 98.58%
2,103 $14,000
Q2 2023

May 21, 2024

BUY
$7.66 - $9.5 $15 - $19
2 Added 0.19%
1,059 $8,000
Q2 2023

Jul 27, 2023

BUY
$7.66 - $9.5 $15 - $19
2 Added 0.19%
1,059 $9,000
Q1 2023

May 21, 2024

BUY
$8.32 - $11.75 $2,204 - $3,113
265 Added 33.46%
1,057 $9,000
Q1 2023

Apr 27, 2023

BUY
$8.32 - $11.75 $2,204 - $3,113
265 Added 33.46%
1,057 $9,000
Q4 2022

May 21, 2024

SELL
$7.65 - $14.43 $114,604 - $216,175
-14,981 Reduced 94.98%
792 $7,000
Q4 2022

Jan 31, 2023

BUY
$7.65 - $14.43 $474 - $894
62 Added 8.49%
792 $7,000
Q3 2022

Oct 21, 2022

BUY
$8.9 - $12.86 $6,497 - $9,387
730 New
730 $8,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $327M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.